Reduced in vitro activity of ceftaroline by Etest among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia

I. J. Abbott, A. W. J. Jenney, Cameron Jeremiah, M. Mirčeta, J P Kandiah, Deborah Holt, Steven Tong, Denis Spelman

    Research output: Contribution to journalArticlepeer-review

    11 Downloads (Pure)

    Abstract

    A total of 421 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates were tested for ceftaroline susceptibility by Etest (bioMeux). A multidrug resistant phenotype was found in 40.9%, and clonal complex 239 (CC239) was found in 33.5%. Ceftaroline nonsusceptibility (MIC, > 1.0 ?g/ml) was 16.9% overall. Nonsusceptibility was significantly higher in CC239 (41.1%, 58/141) and in isolates with a multidrug resistant phenotype (35.5%, 61/172) compared with comparators (P<0.0001). Nonsusceptibility of common multidrug resistant MRSA clones limits the empirical use of ceftaroline for these infections. 
    Original languageEnglish
    Pages (from-to)7837-7841
    Number of pages5
    JournalAntimicrobial Agents and Chemotherapy
    Volume59
    Issue number12
    DOIs
    Publication statusPublished - Dec 2015

    Fingerprint

    Dive into the research topics of 'Reduced in vitro activity of ceftaroline by Etest among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia'. Together they form a unique fingerprint.

    Cite this